Clearside Biomedical, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
CLSD Nasdaq 2834 clearsidebio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Clearside Biomedical, Inc.

Clearside Biomedical Data Featured in Six Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting - May 9th, 2025 11:05 am
Clearside Biomedical to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025 - May 8th, 2025 11:05 am
Will Clearside Biomedical, Inc. (CLSD) Report Negative Q1 Earnings? What You Should Know - May 1st, 2025 2:01 pm
Clearside Biomedical to Participate in a Fireside Chat at the Citizens Life Sciences Conference - May 1st, 2025 11:05 am
Clearside Biomedical Inc (CLSD) Q4 2024 Earnings Call Highlights: Strategic Advances and ... - Apr 2nd, 2025 1:00 am
Clearside Biomedical to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference - Apr 1st, 2025 11:05 am
Clearside Biomedical Full Year 2024 Earnings: In Line With Expectations - Mar 29th, 2025 12:38 pm
Clearside Biomedical, Inc. (CLSD) Reports Q4 Loss, Tops Revenue Estimates - Mar 27th, 2025 9:20 pm
Clearside Biomedical Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - Mar 27th, 2025 8:05 pm
Clearside Biomedical Announces Six Abstracts Accepted for Presentation at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting - Mar 24th, 2025 11:05 am
Clearside Biomedical’s Lead Clinical Program CLS-AX in Wet AMD and Suprachoroidal Delivery Platform Highlighted at the 2025 Wet AMD & Diabetic Eye Disease Summit - Mar 20th, 2025 11:05 am
Clearside Biomedical to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on Thursday, March 27, 2025 - Mar 12th, 2025 11:05 am
Clearside Biomedical Announces Successful End-of-Phase 2 Meeting with the FDA and Alignment on Phase 3 Plans for Suprachoroidal CLS-AX in Wet AMD - Mar 6th, 2025 12:05 pm
Zai Lab Limited (ZLAB) Surges 9.0%: Is This an Indication of Further Gains? - Feb 24th, 2025 3:25 pm
Clearside Biomedical’s Asia-Pacific Partner, Arctic Vision, Announced Acceptance of its New Drug Application for ARCATUS® for Regulatory Review in China for the Treatment of Uveitic Macular Edema - Feb 20th, 2025 12:05 pm
Clearside Biomedical Announces Additional Data from the CLS-AX ODYSSEY Phase 2b Trial Presented at the Angiogenesis, Exudation, and Degeneration 2025 Meeting - Feb 10th, 2025 12:05 pm
Clearside Biomedical to Participate in Fireside Chat at the Oppenheimer 35th Annual Healthcare Life Sciences Virtual Conference - Feb 4th, 2025 12:05 pm
Clearside Biomedical Announces Multiple Medical Meeting Presentations Focused on the Advantages of Suprachoroidal Delivery and Key Differentiators in its CLS-AX Clinical Program - Jan 28th, 2025 12:05 pm
Clearside Biomedical Announces its Asia-Pacific Partner, Arctic Vision, Received Approval of Suprachoroidal Treatment for Uveitic Macular Edema in Australia and Singapore - Jan 22nd, 2025 12:05 pm
Clearside announces publication of insights on drug development, regulation - Dec 20th, 2024 12:16 pm